INVENTING A NEW
ROADMAP FOR BIOTECH
Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases.
Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in four FDA-approved medicines and numerous product candidates in a range of diseases, including ophthalmology, rheumatoid arthritis, atopic dermatitis, asthma, pain, cancer and infectious diseases.
In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human genetics sequencing efforts in the world and rapid response technologies being used for global good.
FOR OVER 25 YEARS, OUR
MISSION HAS BEEN TO USE
THE POWER OF SCIENCE
TO BRING NEW MEDICINES
TO PATIENTS...OVER AND
REGENERON BY THE NUMBERS
years of scientific
an MD, PhD or
ranking in Science
magazine’s global Top
Employer survey for four
of the past six years
volunteer hours at 66
Regeneron in the
Community program in 2015
in greenhouse gas
employee in 2015
of drug candidates
antibodies in clinical
trials across multiple
Fortune: 100 Best Companies to Work For, 2017
Science: #1 Top Employer, 2016
Barron's: World's Best CEOs, 2016
Forbes: #3 World's Most Innovative Companies, 2016
Crain's New York Business: Fast 50, 2015
Shingo Prize (Bronze Medallion): Operational Excellence, 2013
Scrip Award: Clinical Advance of the Year, 2013
Scrip Award: Management Team of the Year, 2013
We are the only biopharmaceutical company to be led by physician-scientists for nearly 30 years. We consistently demonstrate our commitment to scientific excellence by counting multiple Nobel Laureates and five members of the National Academy of Sciences among our leadership, as well as being one of the first companies to form a Science and Technology Committee as an integral component of its Board, a practice which has since become industry standard.
From our first days, science has remained our central guiding principle.